JP2011504872A5 - - Google Patents

Download PDF

Info

Publication number
JP2011504872A5
JP2011504872A5 JP2010511295A JP2010511295A JP2011504872A5 JP 2011504872 A5 JP2011504872 A5 JP 2011504872A5 JP 2010511295 A JP2010511295 A JP 2010511295A JP 2010511295 A JP2010511295 A JP 2010511295A JP 2011504872 A5 JP2011504872 A5 JP 2011504872A5
Authority
JP
Japan
Prior art keywords
antibody
composition
complement
fragment
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010511295A
Other languages
English (en)
Japanese (ja)
Other versions
JP5683265B2 (ja
JP2011504872A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/065771 external-priority patent/WO2008154251A2/en
Publication of JP2011504872A publication Critical patent/JP2011504872A/ja
Publication of JP2011504872A5 publication Critical patent/JP2011504872A5/ja
Application granted granted Critical
Publication of JP5683265B2 publication Critical patent/JP5683265B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010511295A 2007-06-07 2008-06-04 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法 Expired - Fee Related JP5683265B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93372107P 2007-06-07 2007-06-07
US60/933,721 2007-06-07
US5506808P 2008-05-21 2008-05-21
US60/055,068 2008-05-21
PCT/US2008/065771 WO2008154251A2 (en) 2007-06-07 2008-06-04 C3b antibodies and methods for the prevention and treatment of complement- associated disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014020001A Division JP5980249B2 (ja) 2007-06-07 2014-02-05 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法

Publications (3)

Publication Number Publication Date
JP2011504872A JP2011504872A (ja) 2011-02-17
JP2011504872A5 true JP2011504872A5 (enExample) 2011-06-02
JP5683265B2 JP5683265B2 (ja) 2015-03-11

Family

ID=39712089

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010511295A Expired - Fee Related JP5683265B2 (ja) 2007-06-07 2008-06-04 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
JP2014020001A Expired - Fee Related JP5980249B2 (ja) 2007-06-07 2014-02-05 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
JP2016145975A Pending JP2016204382A (ja) 2007-06-07 2016-07-26 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014020001A Expired - Fee Related JP5980249B2 (ja) 2007-06-07 2014-02-05 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
JP2016145975A Pending JP2016204382A (ja) 2007-06-07 2016-07-26 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法

Country Status (18)

Country Link
US (2) US8012473B2 (enExample)
EP (1) EP2162470A2 (enExample)
JP (3) JP5683265B2 (enExample)
KR (3) KR20150029002A (enExample)
CN (1) CN101809034B (enExample)
AR (1) AR066916A1 (enExample)
AU (1) AU2008262048B2 (enExample)
BR (1) BRPI0812767A2 (enExample)
CA (1) CA2690124A1 (enExample)
CL (1) CL2008001656A1 (enExample)
IL (1) IL201820A0 (enExample)
MX (1) MX2009013082A (enExample)
PE (1) PE20090416A1 (enExample)
RU (1) RU2473563C2 (enExample)
SG (2) SG10201608952QA (enExample)
TW (2) TWI441832B (enExample)
WO (1) WO2008154251A2 (enExample)
ZA (1) ZA200907575B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2011084496A1 (en) * 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
WO2011123044A1 (en) * 2010-03-31 2011-10-06 Anamar Ab Method to detect tissue degradation leading to inflammation
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
AU2011336702B2 (en) * 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CA2869477C (en) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
HK1218300A1 (zh) * 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
KR101834469B1 (ko) 2013-08-07 2018-03-06 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
DK3107935T3 (da) * 2014-02-26 2020-09-21 Allergan Inc Komplementkomponent c5-antistoffer
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
ES2895029T3 (es) 2014-06-12 2022-02-17 Ra Pharmaceuticals Inc Modulación de actividad del complemento
AU2015304079B2 (en) * 2014-08-20 2021-05-13 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
HUE056613T2 (hu) 2015-01-28 2022-02-28 Ra Pharmaceuticals Inc Komplementaktivitás modulátorai
RU2584582C1 (ru) * 2015-03-16 2016-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело сс3-4 к конформационному эпитопу с3 человека, штамм гибридной днк мыши рккк(п)764д - продуцент моноклонального антитела сс3-4
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
CA3054167A1 (en) * 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
CN111683672A (zh) 2017-12-04 2020-09-18 Ra制药公司 补体活性调节剂
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
TWI833742B (zh) * 2018-04-03 2024-03-01 美商恩格姆生物製藥公司 Ｃ３結合劑及其使用方法
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
EP3801772A1 (en) 2018-06-11 2021-04-14 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
GB201821089D0 (en) 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
TW202102481A (zh) 2019-03-29 2021-01-16 美商Ｒａ製藥公司 補體調節劑和相關方法
BR112021017820A2 (pt) 2019-04-24 2022-02-08 Ra Pharmaceuticals Inc Composições e métodos para modulação da atividade de complemento
EP3980047B1 (en) 2019-06-04 2024-02-14 RA Pharmaceuticals, Inc. Inflammatory disease treatment with complement inhibitors
BR112022000739A2 (pt) 2019-07-17 2022-04-12 Gemini Therapeutics Sub Inc Anticorpos de potencialização de fator h e usos dos mesmos
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
AU2023260823A1 (en) * 2022-04-29 2024-11-14 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
EP4582445A1 (en) 2022-08-30 2025-07-09 Longbio Pharma (Suzhou) Co., Ltd. Anti-human complement c5 antibody and fusion protein thereof
AU2023347940A1 (en) * 2022-09-20 2025-03-27 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b-antibodies
JP2025537300A (ja) 2022-11-10 2025-11-14 ロングバイオ ファーマ （スーチョウ） カンパニー、リミテッド 補体阻害ハイブリッドタンパク質突然変異体および抗体とその融合タンパク質
WO2024227154A1 (en) * 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
CZ283598A3 (cs) * 1996-03-07 1999-02-17 Imutran Ltd. C3-konvertáza rezistentní k regulačnímu snížení aktivity
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
CN101298481A (zh) * 1998-02-20 2008-11-05 吉宁特有限公司 补体活化的抑制剂
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof

Similar Documents

Publication Publication Date Title
JP2011504872A5 (enExample)
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP7293122B2 (ja) 補体が媒介する疾患および障害を処置するための方法
CN108473566B (zh) 抗N3pGlu淀粉样蛋白β肽抗体及其用途
JP2010528047A5 (enExample)
JP6608698B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
JP2016526393A5 (enExample)
JP2017500018A5 (enExample)
JP2016504416A5 (enExample)
JP2016529255A5 (enExample)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2012165745A5 (enExample)
JP2016117771A (ja) 抗Ｃ５ａ抗体およびその抗体の使用のための方法
JP2017535285A5 (enExample)
TW201014602A (en) Prostaglandin E2 binding proteins and uses thereof
FI3019240T3 (fi) Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä
RU2018125515A (ru) Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2018511609A5 (enExample)
JP2019505527A5 (enExample)
JP2018093875A5 (enExample)
JP7572041B2 (ja) 重症喘息を処置するための組成物および方法
JP2018530574A5 (enExample)
TW200803898A (en) Novel use of 1L-1beta compounds
JP2018529661A5 (enExample)
JP2011503094A5 (enExample)